Genentech, which lost 12 percent of its stock value in 2006. According to the consensus forecast from Thomson, the stock price will rise 19 percent in 2007, with an EPS surge of 23 percent for the full year. Future earnings for Genentech, the …
Plaintiff Ira Gaines is an individual investor who holds Genentech stock, Toll said. The lawsuit contends Roche’s bid was timed to capitalize on general market turmoil and a decline in Genentech’s stock price. Both Genentech and Roche are …
Genentech Inc.'s stock slipped 5.3% on Tuesday as investors winced at news that the U.S. attorney's office in Philadelphia was conducting an investigation into the marketing of the firm's top-selling drug, Rituxan. Shares in the world's second …
Genentech, Inc. (NYSE:DNA) has announced that the biotech giant has authorized the extension of its current stock repurchase program through June 30, 2009 and it amended the current repurchase program. It is increasing the …
Genentech stock came under pressure Thursday morning after the firm invited analysts to the briefing. The stock closed off 25 cents, to $26.75, on the New York Stock Exchange. The announcement of free treatment for some patients …
The media and stock market are again atwitter with news of another supposed cancer breakthrough. Avastin (search), a drug developed by biotech giant Genentech (search), reportedly extended the median survival time of terminally ill colon …
The development of risdiplam RG7916 is being executed globally by Roche, …
Biotechnology firms MedImmune and Genentech settled a lawsuit over a patented ... Fourth-quarter sales of Synagis were $480 million. Genentech's stock rose 67 cents yesterday, to $68.89, and AstraZeneca's shares rose 1 cent, to $44.01.
Genentech rose $2.29, or 2.5 percent, to $94.46 in trading before the New York Stock Exchange opened. The world's biggest drugmakers, armed with about $100 billion in cash and short-term investments, are seeking acquisitions to …
Under the terms of the deal, Roche would own about 60 percent of Genentech’s voting stock. Roche exercises a call option to buy the portion of Genentech it does not own, then reissues up to 19 percent of the stock, preserving the biotech’s …